Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Endologix, Inc. (ELGX), Quest Diagnostics Inc (DGX), The Spectranetics Corporation (SPNC), and More: Tamarack Capital’s Top Picks

Page 1 of 2

Justin John Ferayorni’s Tamarack Capital Management has filed their latest 13F with the US Securities and Exchange Commission, revealing their long equity positions as of December 31 of last year. The top five is mostly unchanged from the end of the third quarter, when Endologix, Inc. (NASDAQ:ELGX) was the fund’s top pick, though one newcomer makes the top five (and a completely new position at that).

Justin John Ferayorni - Tamarack Capital Management

Justin Ferayorni founded Carlsbad, California-based Tamarack Capital Management in 2010, after previously working as an analyst and portfolio manager at Bricoleur Capital, and before that at John Galt Capital, Robertson Stephens & Co., and Atlantic-ACM. The hedge fund has a focus on the healthcare industry, with 73.4% of its equity tied up in the sector at the end of 2014. Tamarack increased many of its positions in the fourth quarter while opening several new ones as well, as the value of its equity portfolio jumped nearly 50%, to $659 million from $451 million at the end of the previous quarter.

Endologix, Inc. (NASDAQ:ELGX) remains Tamarack’s top long position, building it by 20% during the quarter to 3.96 million shares, giving them a 5.96% passive stake in the maker of healthcare devices specifically targeted for the treatment of aortic disorders, in particular abdominal aortic aneurysms, one of the highest causes of death in the United States.

Shares in the company went on a torrid run from the beginning of 2009 to the end of 2013, rising 1,628% during that five-year span. Since the beginning of 2014 however, shares have slid 17.25% on the back of weak financial results. Their most recent results, for the third quarter of 2014, came in below estimates, with reveue of $37.2 million and a net loss of $0.13 per share. The company will release its fourth quarter and full-year results for 2014 on February 25.

Quest Diagnostics Inc (NYSE:DGX) is a new position for Tamarack, and slides into the second spot on the listing of their most valuable positions. Quest Diagnostics is a stock that mostly treaded water for nearly a decade before finally breaking out in 2014, gaining 23.96% for the year, and has carried that momentum into 2015, up another 6.84% year-to-date.

Why did Quest Diagnostics Inc (NYSE:DGX) suddenly break out? They made great strides towards the end of 2013 to refocus their business on higher growth areas like esoteric testing, including selling off the royalty rights to ibrutinib for $485 million which generated a good deal of capital to return value to shareholders, including raising dividends another 10% beginning in April, 2014. Financials have also impressed, with the company’s recent preliminary full-year results revealing revenue of $7.44 billion for the year and earnings of $3.81 per share.

Quest Diagnostics Inc (NYSE:DGX) expects continued growth throughout 2015 as the uptake of patients through the Affordable Care Act continues to increase the potential pool of insured patients.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!